Weight loss and glycemic control, through lifestyle modification, pharmacotherapy (e.g., GLP-1 receptor agonists), or bariatric surgery, have been shown to reduce the risk of obesity-related and diabetes-associated cancers [22-24]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.